Placental Transfer of Anti-Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 3, 2013, Pages 286-292

  Mahadevan, Uma ^a   Wolf, Douglas C ^b   Dubinsky, Marla ^c   Cortot, Antoine ^d   Lee, Scott D ^e   Siegel, Corey A ^f   Ullman, Thomas ^g   Glover, Sarah ^h,i   Valentine, John F ^j   Rubin, David T ^k   Miller, Jocelyn ^l   Abreu, Maria T ^m  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Atlanta Gastroenterology Associates   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d Hepato Gastroenterolgie Cite Hospitaliere   (France)

^e UNIVERSITY OF WASHINGTON   (United States)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF ILLINOIS   (United States)

ⁱ UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^j UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF CHICAGO   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Crohn's Disease; Pregnancy; Safety; Treatment; Ulcerative Colitis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB;

ADULT; ADVERSE OUTCOME; ARTICLE; BIRTH; CASE REPORT; CONGENITAL MALFORMATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SAFETY; ENTERITIS; FEMALE; HUMAN; PLACENTAL TRANSFER; PREGNANT WOMAN; UMBILICAL CORD BLOOD; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FETAL BLOOD; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOLOGIC FACTORS; INFANT; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; POLYETHYLENE GLYCOLS; PREGNANCY; PREGNANCY COMPLICATIONS; SERUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874576191     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.11.011     Document Type: Article

References (29)

1. Mahadevan U., Sandborn W.J., Li D.K., et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007, 133:1106-1112.
2. Nørgård B., Hundborg H.H., Jacobsen B.A., et al. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol 2007, 102:1947-1954.
3. D'Haens G.R., Panaccione R., Higgins P.D., et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol 2011, 106:199-212. quiz, 213.
4. Mahadevan U., Cucchiara S., Hyams J.S., et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011, 106:214-223. quiz, 224.
5. Palmeira P., Quinello C., Silveira-Lessa A.L., et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012, 2012:985646.
6. Simister N.E. Placental transport of immunoglobulin G. Vaccine 2003, 21:3365-3369.
7. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
8. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333. quiz, 591.
9. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357:228-238.
10. Nesbitt A., Brown D., Stephens S., et al. Placental transfer and accumulation in milk of the anti-TNF antibody TN3 in rats: immunoglobulin G1 versus PEGylated Fab' (abstr). Am J Gastroenterol 2006, 101:S420-S470.
11. Mahadevan U., Martin C., Sandler R.S., et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy (abstr). Gastroenterologist 2012, 142:S-149.
12. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
13. Vasiliauskas E.A., Church J.A., Silverman N., et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006, 4:1255-1258.
14. Zelinkova Z., de Haar C., de Ridder L., et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011, 33:1053-1058.
15. Kane S., Ford J., Cohen R., et al. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009, 43:613-616.
16. Peltier M., James D., Ford J., et al. Infliximab levels in breast-milk of a nursing Crohn's patient. Am J Gastroenterol 2001, 96:P258-P259.
17. Ben-Horin S., Yavzori M., Kopylov U., et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 2011, 5:555-558.
18. Ben-Horin S., Yavzori M., Katz L., et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 2010, 8:475-476.
19. Katz J.A., Antoni C., Keenan G.F., et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004, 99:2385-2392.
20. Mahadevan U., Kane S., Sandborn W.J., et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005, 21:733-738.
21. Schnitzler F., Fidder H., Ferrante M., et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011, 17:1846-1854.
22. Coburn L.A., Wise P.E., Schwartz D.A. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig Dis Sci 2006, 51:2045-2047.
23. Mishkin D.S., Van Deinse W., Becker J.M., et al. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis 2006, 12:827-828.
24. Vesga L., Terdiman J.P., Mahadevan U. Adalimumab use in pregnancy. Gut 2005, 54:890.
25. Chambers C.D., Johnson D.L., Jones K.L. Adalimumab and pregnancy outcome: the OTIS autoimmune diseases in pregnancy project. Am J Gastroenterol 2006, 101:S421-S422.
26. Carter J.D., Ladhani A., Ricca L.R., et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the food and drug administration database. J Rheumatol 2009, 36:635-641.
27. Cheent K., Nolan J., Shariq S., et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010, 4:603-605.
28. Mahadevan U., Kane S., Church J., et al. The effect of maternal peripartum infliximab use on neonatal immune response (abstract). Gastroenterology 2008, 134:A-69.
29. Arpino C., Compagnone E., Montanaro M.L., et al. Preterm birth and neurodevelopmental outcome: a review. Childs Nerv Syst 2010, 26:1139-1149.